Wellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA.
PM R. 2010 Dec;2(12 Suppl 2):S292-305. doi: 10.1016/j.pmrj.2010.10.013.
This year marks the 50th anniversary of the discovery of the laser. The development of lasers for medical use, which became known as low-level laser therapy (LLLT) or photobiomodulation, followed in 1967. In recent years, LLLT has become an increasingly mainstream modality, especially in the areas of physical medicine and rehabilitation. At first used mainly for wound healing and pain relief, the medical applications of LLLT have broadened to include diseases such as stroke, myocardial infarction, and degenerative or traumatic brain disorders. This review will cover the mechanisms of LLLT that operate both on a cellular and a tissue level. Mitochondria are thought to be the principal photoreceptors, and increased adenosine triphosphate, reactive oxygen species, intracellular calcium, and release of nitric oxide are the initial events. Activation of transcription factors then leads to expression of many protective, anti-apoptotic, anti-oxidant, and pro-proliferation gene products. Animal studies and human clinical trials of LLLT for indications with relevance to neurology, such as stroke, traumatic brain injury, degenerative brain disease, spinal cord injury, and peripheral nerve regeneration, will be covered.
今年是激光发现 50 周年。1967 年,激光在医学上的应用发展起来,被称为低水平激光疗法(LLLT)或光生物调节。近年来,LLLT 已成为一种越来越主流的治疗方式,特别是在物理医学和康复领域。起初主要用于伤口愈合和缓解疼痛,LLLT 的医学应用已经扩展到包括中风、心肌梗死和退行性或外伤性脑疾病等疾病。这篇综述将涵盖 LLLT 在细胞和组织水平上的作用机制。线粒体被认为是主要的光感受器,而三磷酸腺苷、活性氧、细胞内钙和一氧化氮的释放是最初的事件。随后转录因子的激活导致许多保护性、抗凋亡、抗氧化和促增殖基因产物的表达。本文将涵盖与神经科相关的 LLLT 适应证的动物研究和临床试验,如中风、创伤性脑损伤、退行性脑疾病、脊髓损伤和周围神经再生。